Localizing vaccine manufacturing and improving the health of Saudi citizens are among the key goals of a new national biotechnology strategy, launched by Crown Prince Mohammed bin Salman.
The new initiative also aims to safeguard the environment, achieve food and water security, and solidify the Kingdom’s position as a global leader in the sector, according to the Saudi Press Agency.
One of the major focuses of the initiative is localizing vaccine manufacturing to increase the Kingdom’s self-sufficiency and ensure timely access to these medicines for its citizens.
Furthermore, the program targets a 3 percent contribution of the biotechnology sector to the non-oil gross domestic product by 2040, with a cumulative impact of SR130 billion ($34.66 billion), in addition to providing thousands of high-quality opportunities and jobs.
These initiatives are aligned with the Kingdom’s Vision 2030 objectives.
“Localization and biomanufacturing play a vital role in driving the strategy forward, as Saudi Arabia aims to establish itself as the primary biotechnology hub in the MENA (Middle East and North Africa) region,” said the SPA report, adding: “Developing advanced biopharma manufacturing capabilities and establishing a cutting-edge local end-to-end bio-manufacturing platform are crucial steps.”
The program focuses on four strategic directions, including vaccines, with an emphasis on localizing vaccine production, exporting, and leading innovation in the field.
Additionally, it prioritizes biomanufacturing, aiming to increase the consumption and localization of biopharmaceuticals. The strategy also highlights genomics, with a focus on pioneering research and gene therapy.
Lastly, plant enhancement is a key aspect, involving efforts to improve cultivation for enhanced self-sufficiency and to lead innovation in enhanced seeds.
The Kingdom, being the largest regional market for pharmaceuticals and vaccines, has strategically invested in biotechnology-related sectors. It is committed to developing and training national talent in research, development, and innovation while enabling a competitive and digital infrastructure.
The country’s genetic diversity and geographical climate provide ideal conditions for conducting complex studies and research.
The strategy aims to empower the local biotechnology industry by streamlining regulatory requirements, providing suitable infrastructure, and offering financing. Through its various programs and initiatives, it seeks to stimulate efforts by private sector investors in this field.
The launch of this national scheme aims to provide a flexible regulatory environment and advanced infrastructure, fostering integration between the public and private sectors.—AN
